Shots:
- Innovent will grant Spero Therapeutics exclusive rights to develop, research, manufacture, & commercialize SP001 worldwide, excl. Greater China, where Innovent will retain the rights
- In return, Innovent will receive an upfront payment & development, regulatory & commercial milestone payments, representing the total deal value of ~$1.1B, plus Innovent will also receive tiered royalties on net sales in Spero’s licensed areas
- SP001 (IBI355) is a third-generation Fc-silent anti-CD40L antibody. Spero plans to initiate a P-II trial in IgG4-related disease in Q2’27, while Innovent expects to begin a P-II study in Sjögren’s disease in China by early 2027
Ref: Globenewswire | Image: Innovent & Spero | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
